subscribeSubscribe
price-trendAsk Us
Clovis Oncology Announces First Patient Enrolled in the Ph2 Portion the LIO-1

Clovis Oncology Announces First Patient Enrolled in the Ph2 Portion the LIO-1
BUSINESSWIRE
04 Aug 2020
Share Share
New Preclinical Data on ALKS 4230 in Comb Lucitanib Presented at 2020 (AACR)

New Preclinical Data on ALKS 4230 in Comb Lucitanib Presented at 2020 (AACR)
PRNEWSWIRE
22 Jun 2020
Share Share
Clovis Oncology to Highlight Rubraca®& Lucitanib Non-Clinical Data at the AACR

Clovis Oncology to Highlight Rubraca®& Lucitanib Non-Clinical Data at the AACR
BUSINESSWIRE
17 Jun 2020
Share Share
Meet the protein responsible for nearly $100B in cancer drug deals

Meet the protein responsible for nearly $100B in cancer drug deals
Jacob Bell BIOPHARMADIVE
17 Aug 2019
Share Share
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib)

Clovis Oncology Announces Interim Results from Rubraca® (rucaparib)
BUSINESSWIRE
02 Apr 2019
Share Share
Clovis loses Servier pact, agrees to settle SEC case

Clovis loses Servier pact, agrees to settle SEC case
Nick Paul Taylor FIERCE BIOTECH
02 Aug 2018
Share Share